An off-the-shelf drug to rival CAR T cells: ‘very exciting’December 13, 2019Lymphoma & Plasma Cell DisordersImmuno-oncologyImmunotherapy
Bispecific CAR T-cells yield high response rate in relapsed/refractory myelomaDecember 7, 2019Immuno-oncologyImmunotherapyLymphoma & Plasma Cell Disorders
High complete response rate seen with novel CAR-T for myelomaDecember 7, 2019Immuno-oncologyImmunotherapyLymphoma & Plasma Cell DisordersRare Diseases
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTENovember 26, 2019Lymphoma & Plasma Cell DisordersImmuno-oncologyImmunotherapy
Combo elicits lasting responses in metastatic melanomaNovember 25, 2019MelanomaImmunotherapyImmuno-oncology
Will TP53-mutated AML respond to immunotherapy?November 18, 2019Leukemia, Myelodysplasia, TransplantationImmunotherapyRare Diseases
CAR T-cell ‘cocktail’ may overcome antigen escape relapseNovember 18, 2019ImmunotherapyLymphoma & Plasma Cell Disorders
Neoantigen vaccine appears safe and active in NSCLCNovember 14, 2019Lung CancerImmunotherapyImmuno-oncology
Combo produces disappointing PFS, promising OS in metastatic colorectal cancerNovember 13, 2019GastroenterologyImmunotherapyImmuno-oncologyGastrointestinal Cancer
Armored CAR T cells elicit responses in NHL patientsNovember 12, 2019DLBCLLymphoma & Plasma Cell DisordersFollicular LymphomaImmunotherapyImmuno-oncology
Combo shows promise for checkpoint inhibitor-refractory urothelial carcinomaNovember 12, 2019Genitourinary CancerImmunotherapyImmuno-oncology
TLR9 agonist may overcome resistance to anti–PD-1 therapy in melanomaNovember 12, 2019MelanomaImmunotherapyImmuno-oncology
Molecule exhibits activity in heavily pretreated, HER2-positive solid tumorsNovember 11, 2019Breast CancerGynecologic CancerGastroenterologyImmunotherapyImmuno-oncologyGastrointestinal Cancer
